Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuCana's R&D On Agents For Drug-Resistant Cancers Gets IPO Boost

Executive Summary

The UK biotech plans to move its early clinical-stage anticancers, designed to improve the efficacy and tolerability of established agents, through its R&D pipeline with the proceeds of its recent US IPO.

Advertisement

Related Content

UK's Nightstar NASDAQ Listing Backs British Biotech Build-Up Strategy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel